bibliographic resource 8212789 [br/8212789]
https://w3id.org/oc/corpus/br/8212789

is a
title
  • Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway–targeted therapy and one prior mTOR inhibitor therapy.
publication date
  • 2014-01-01
contributor
format
identifier
part of